Aprameya Medtech partners with SonoScape for surgical imaging
Aprameya Engineering Limited’s subsidiary Aprameya Medtech Private Limited signed an exclusive sales and marketing agreement with Sonoscape Medical India Private Limited for advanced surgical imaging systems in Southern and Western India. The partnership includes a range of 4K and FHD visualization platforms for various hospital segments. The companies also plan to evaluate local manufacturing of these systems in India.
*this image is generated using AI for illustrative purposes only.
Aprameya Engineering Limited announced that its 70%-owned subsidiary, Aprameya Medtech Private Limited, has entered into a strategic marketing agreement with Sonoscape Medical India Private Limited. The agreement grants Aprameya Medtech exclusive rights to sell and market SonoScape’s advanced Minimally Invasive Surgery (MIS) portfolio across Southern and Western India. This partnership aims to transform Aprameya from a project-led business into an integrated Healthcare Infrastructure and Medical Equipment platform.
The alliance leverages SonoScape’s technology, which serves clinicians in over 170 countries. SonoScape Medical Corp. is a publicly listed entity that integrates ultrasound, endoscopy, and surgical visualization under one roof, supported by 7 global R&D centres and over 1,035 patents. The collaboration intends to bring high-margin medical equipment sales to complement Aprameya’s existing hospital infrastructure projects.
The product portfolio includes visualization platforms ranging from value-focused full-HD systems to flagship 4K NIR 3D towers. These systems are designed for various hospital segments, from premium tertiary care centres to value-conscious tier-2 and tier-3 hospitals.
| Platform / System | Hospital Segment | What It Delivers |
|---|---|---|
| SV-M4K220Exp — 4K NIR 3D (Flagship) | Premium tertiary & oncology centres | Ultra-sharp 4K vision, fluorescence imaging, and 3D depth perception |
| SV-M4K40 — 4K NIR | Advanced surgical & cancer care | 4K vision with fluorescence (ICG) guidance for real-time tumour location |
| SV-M4K30 / SV-M4K120Exp — 4K | Mainstream multi-specialty hospitals | Ultra-HD camera platforms for laparoscopic workload |
| SV-M2K30 / X-2600 — FHD | Value-conscious & tier-2/3 hospitals | Accessible full-HD systems for keyhole surgery |
| Rigid Endoscopes & Auxiliary Devices | All segments | Laparoscopes, telescopes, and insufflators for recurring revenue |
Strategic Rationale and Future Plans
The partnership targets a structurally growing market for minimally invasive surgical devices in India, projected to roughly double by 2033. Aprameya Medtech plans to build a dedicated MIS vertical encompassing clinical demonstrations, surgeon training, installation, and after-sales service. Additionally, the companies intend to evaluate manufacturing these systems in India, aligned with the Government of India’s ‘Make in India’ vision. Aprameya Medtech’s upcoming ~45,000 sq. ft. facility, expected operational by the end of CFY 2026–27, may support this localisation effort.
Historical Stock Returns for Aprameya Engineering
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.86% | -4.57% | -33.69% | -50.60% | -10.06% | +105.82% |
What is the expected timeline for the joint evaluation of local manufacturing, and could the 'Make in India' initiative significantly alter the cost structure of these 4K systems?
How will the capital expenditure for the upcoming 45,000 sq. ft. facility impact Aprameya Engineering's cash flow and profitability in the short term?
What specific revenue contribution is management targeting from the high-margin medical equipment vertical versus the traditional project-led business over the next three years?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
